Osteoarthritis (OA), the most common form of arthritis, is a chronic degenerative joint disease that remains a leading cause of chronic disability in the aged population and a financial burden on healthcare resources. It affects approximately 15% of the world’s human population over 60 years of age (Wolf & Pfleger, 2003) and has even higher prevalence in dogs (Johnston, 1997), cats (Godfrey, 2005) and horses (Trumble et al., 2001). It is established that OA in dogs and horses has a model character for the human disease since it parallels the human form of OA in all aspects (Innes & Clegg, 2010).
The pathogenesis of OA is characterized by an imbalance in the network of anabolic and catabolic processes through complex interactions of mechanical and biochemical forces (M.B. Goldring, 2001; Sandell & Aigner, 2001). This imbalance leads, inevitably, to progressive articular cartilage destruction, osteophyte formation, subchondral bone remodelling and chronic inflammation (M.B. Goldring & S.R. Goldring, 2007; Martel-Pelletier & Pelletier, 2007). These events are further manifested by a loss of both tissue architecture and joint functionality, painful limited movement, disability and an inferior quality of life (Abramson & Yazici, 2006; Buckwalter et al., 2006; Pelletier et al., 2001). Despite major progress over the last few years, we still have a lot more to understand about the aetiology, pathogenesis and progression of OA.
A complete therapy for OA still remains elusive as manifold efforts made in this direction failed to provide a successful long-term remedy. The therapeutic strategies for OA have been predominantly directed to (i) alleviate symptomatic pain by suppressing the inflammatory process, (ii) reducing the cartilage degenerative process or (iii) enhancing cartilage regeneration. However, none has so far been applied to achieve all the three objectives.
Non-pharmacologic and pharmacologic treatments have been employed for early OA while surgical interventions for partial or total joint replacement are often indicated in advanced OA when the symptoms cannot be controlled by non-invasive means. The long-term use of pharmacologics is commonly concomitant with side-effects while surgery contributes little to reduce the process of joint destruction and inflammation (Katz et al., 2010; Wei et al., 1998).
Articular cartilage destruction is a key pathological characteristic of OA and rheumatoid arthritis (RA). Therefore, attempts have been made to repair the OA-related cartilage defects. In this context, autologous chondrocyte transplantation (ACT) offers a practical solution (Brittberg et al., 1994). Evidence suggests that damaged cartilage plays a pivotal role in disease progression and severity (Buckwalter et al., 2006). ACT attempts to build hyaline repair tissue, delays total or partial joint replacement, helps to temporarily relieve pain and improves the joint function (Minas et al., 2010; Peterson et al., 2002). A further developed alternative technique is the matrix associated ACT, where the cultivated cells are seeded on a tissue-engineered (biomaterial) scaffold and the cell–scaffold complex is then implanted into the defect. The ACT/scaffold coupling paved the way for the use of functional tissue substitutes in the treatment of cartilage defects (Tuli et al., 2003). However, inflammatory mediators in the arthritic joint could negatively affect the implanted cells, potentiating the need to suppress inflammation (Hennerbichler et al., 2008).
Gene therapy represents another promising approach for OA treatment (Bandara et al., 1992; Evans et al., 2004; Evans et al., 2009). This concept utilizes viral or non-viral vectors to deliver genetic information encoding biological agents into the target tissue for their local expression. It appears that viral strategies provide high transfection efficiency and many additional assets for a clinical development (Mease et al., 2010) but immunogenicity and possible mutagenicity are their main drawbacks. Non-viral strategies, on the other hand, have a fascinating preclinical development in arthritis. They are safer but less efficient. Of major concern is the regulated expression of the therapeutic genes. Ideally, gene therapy outperforms the systemic intake of medicines by only affecting the transfected joint. Normally, drugs can be applied in a controlled dosage, while transgene expression is switched by intrinsic, normally immutable, regulatory elements. In other words, the expression of the therapeutic candidate gene should be limited to the site of OA occurrence and only applied in the presence of inflammation or other significant markers of OA arising in the affected joint. Moreover, the gene expression should ideally be self-limiting (=conditioned) and not constitutive (Geurts et al., 2007; Rachakonda et al., 2008a).
The information presented above provides evidence for a limited success of several efforts towards achieving effective therapeutic strategies for OA. This is mainly because they are associated with one or the other limitation. Nonetheless, it is tempting to speculate that gene therapy (coupled with tissue-engineering) has great potential for improvement. It is therefore very likely that it becomes a leading force for future OA treatment if suitably improved. This chapter will provide extended information on this topic and discuss as well as suggest some novel ways to improve the current gene therapy procedures for their safe application.
2. Non-pharmacological and pharmacological therapies
Pain is the presenting symptom in OA. Thus, the therapeutic efforts for OA specifically aim at the pain relief through the combination of non-pharmacological and pharmacological interventions. Non-pharmacological approaches include exercise therapy, weight loss, social support, self-management and awareness of patients to OA (Clouet et al., 2009). These approaches help partially prevent the disease, reduce pain and may delay the degenerative process in early-stage OA but do not offer a long-term remedy. Pharmacological therapy improves the quality of life of OA patients also through alleviating pain. Acetaminophen treatment followed by non-steroidal anti-inflammatory drugs (NSAIDs) inhibits the activation of immune cells while NSAIDs suppress the inflammatory process by intervening with the prostaglandin synthesis. Long-term usage of NSAIDs is often accompanied by adverse side-effects such as gastrointestinal, renal or cardiovascular disorders, as most of these compounds inhibit cyclooxygenases (COX)-1 and -2 indiscriminatorily (Hotz-Behofsits et al., 2003; Scarpignato & Hunt, 2010; Wolfe et al., 1999).
Selective COX-2 inhibitors reduce pain through prostaglandin blockade, but owing to their harmful effects on cardiovascular events they were recalled from the market (Park et al., 2006). Later on, the application of some disease-modifying OA drugs (DMOADs) was being enhanced by advances in imaging and biomarkers that serve as validated surrogate endpoints for key clinical outcomes (Abramson & Yazici, 2006). However, the clinical development program for DMOADs is complicated due to the slowly progressive nature of OA.
Intra-articular injections of corticosteroids (Habib et al., 2010) or hyaluronic acid (Liao et al., 2005) exert pain reducing effects that last for a couple of weeks but do not significantly improve the physical function of the joint. Nutritional supplements such as chondrotin sulphate and glucosamine are asymptomatic slow-acting safe drugs for the management of OA, but their efficacy in OA is questionable (Dougados, 2006) just like avocado, soybean, unsaponifiables and Vitamin E (Clouet et al., 2009).
3. Surgical treatment
Surgical intervention offers another option for OA therapy after medications have failed to restore joint function. Arthroscopic lavage and debridement of the arthritic joint is only indicated in cases of superimposed structural lesions in the affected joint such as meniscal tear (Katz et al., 2010). Osteotomy is performed by trimming the joint resulting in a spread of the mechanical load which relieves the defect area (Parker et al., 2011). Partial or total joint replacements are the last resorts in orthopaedic surgery for OA. But these procedures are more prone to fail in young and middle-aged patients (Wei et al., 1998). In addition, the evidence supporting the use of various surgical approaches is limited mainly by the poor study design and relatively small sample size (Katz et al., 2010).
4. Concept of gene therapy in OA
The term gene therapy is commonly understood to mean the use of molecular methods to replace defective or absent genes or to counteract those that are over-expressed. The key technologies needed for gene therapy are the methods by which genes are isolated (cloned), manipulated (engineered), and transferred (delivered) into host cells. Since its inception, the field of gene therapy in medicine has received much attention, but still remains a great challenge for routine clinical applications to treat diseases including OA and RA (Gibbons & Hyrich, 2009).
In vivo gene delivery in the arthritic joint
OA is well-suited for local, intra-articular gene delivery because it affects a limited number of joints and lacks obvious extra-articular manifestations (Bandara et al., 1992). Thus, the delivery of locally expressed gene products may have therapeutic benefits for localized areas of cartilage damage with minimal systemic side-effects. In this approach genes encoding biological agents are introduced directly into the intra-articular tissues through viral and non-viral vectors. Despite its simplicity, the
|Adenovirus||IL-1Ra||Dog ACLT||Pelletier et al., 1997|
|Plasmid||IL-1Ra||Rabbit meniscectomy||Fernandes et al., 1999|
|Adenovirus||IL-1Ra||Horse osteochondral defects||Frisbie et al., 2002|
|rAAV||bFGF||Rabbit osteochondral defects||Cucchiarini & Madry, 2005|
|Plasmid||BMP-2||Rabbit cartilage defects||Di Cesare et al., 2006|
|Plasmid||HSP-70||Rat MIA injection||Grossin et al., 2006|
|Adenovirus||TSP-1||Rat ACLT||Hsieh et al., 2010|
Ex vivo gene delivery in arthritic joint
An efficient targeting of specific types of cells
4.3. Selective anti-catabolic gene products
The pro-inflammatory cytokines interleukin-1 beta (IL-1β) and tumour necrosis factor alpha (TNFα) secreted by chondrocytes, synovial cells and invading immune cells, are important mediators of matrix degeneration and cell apoptosis in OA (M.B. Goldring, 2001). Therefore, inhibitors of these cytokines may counteract inflammatory destruction of cartilage. Besides cytokines, matrix metalloproteinases (MMPs) and aggrecanases such as ADAMTS-4 (a disintegrin and metalloproteinase with thrombospondin-like motif-4) and -5 (ADAMTS-5) secreted by the chondrocytes degrade a surplus of matrix in OA (Heinegård & Saxne, 2011). In order to diminish the lysis of cartilage and thus to reduce OA progression, tissue inhibitors of metalloproteinases (TIMPs) can be over-expressed through gene therapy (Celiker et al., 2002; van der Laan et al., 2003).
|Chondrocytes||LacZ-neo||Retrovirus||Rabbit||Kang et al., 1997|
|BMP-7||Adenovirus||Horse||Hidaka et al., 2003|
|IGF-1||Plasmid||Rabbit||Madry et al., 2005|
|bFGF||rAAV||Rabbit||Yokoo et al., 2005|
|bFGF||Plasmid||Rabbit||Kaul et al., 2006|
|Synovial cells||LacZ-neo||Retrovirus||Rabbit||Bandara et al., 1992|
|Retrovirus||Rabbit||Zhang et al., 2004|
|Perichondrium-derived stem cells||BMP-1|
|Adenovirus||Rat||Gelse et al., 2003|
|Bone-marrow-derived stem cells||CDMP1||Plasmid||Rabbit||Katayama et al., 2004|
|Fibroblasts||TGF-β||Retrovirus||Rabbit||Lee et al., 2001|
|Muscle-derived cells||LacZ||Retrovirus||Rabbit||Adachi et al., 2002|
4.4. Selective anabolic gene products
While inhibition of catabolic pathways will diminish OA damage, it will not enhance repair of already degraded matrix. Therefore, gene products with anabolic functions are of special interest. These gene products comprise anabolic enzymes and growth factors that promote matrix synthesis and morphogenic mediators for chondrogenic differentiation. Matrix synthesis can be enhanced by expressing enzymes required for the synthesis of precursors of matrix constituents (J.N. Gouze et al., 2004). An overview of genes employed for OA gene therapy is provided in Table 3.
|IL-1Ra||Blocks IL-1R on articular cells||Evans & Robbins, 1994|
|sIL-1R||Neutralizes secreted IL-1||Ghivizzani et al., 1998|
|sTNFR||Neutralizes secreted TNFα||Ghivizzani et al., 1998|
|IL-4||Down-regulates IL-1 and TNFα expression||Geurts et al., 2007; Rachakonda et al., 2008a; Woods et al., 2001|
|IL-10||Down-regulates IL-1 and TNFα expression||Amos et al., 2006; Müller et al., 2008; Zhang et al., 2004|
|IL-13||Anti-inflammatory action||Nabbe et al., 2005|
|TIMPs||Matrix proteinase inhibitor||Celiker et al., 2002; van der Laan et al., 2003|
|IGF-1||Chondrocyte growth factor||Madry et al., 2002|
|TGF-β||Chondrocyte growth factors||Lafeber et al., 1997; Watson et al., 2010|
|BMPs||Chondrocyte growth factors||Hidaka et al., 2003|
|bFGF||Chondrocyte growth factor||Madry et al., 2004|
|SOX-9||Transcription factor||Cucchiarini et al., 2007|
|GFAT||Enhances matrix synthesis||J.N. Gouze et al., 2004|
|GlcAT-I||Enhances matrix synthesis||Venkatesan et al., 2004|
4.5. Viral gene transfer
Viruses provide a natural system for horizontal gene transfer into a variety of cells. Several virus types (given below) infect mammalian cells and are adopted as vehicles for gene transfer. Retroviral transfection systems derived from Moloney murine leukaemia oncoretrovirus and others require dividing cells for infection and integration and have therefore been used mainly in
Lentiviruses, derived from the human immunodeficiency virus, are able to infect resting-state cells with high efficiency, show low immunogenicity and can integrate transgenes into the cell DNA. To avoid possible insertion mutagenesis, non-integrating lentiviruses have been developed which maintain the high transduction efficiency (Philpott & Thrasher, 2007) and can be used for
Adenoviruses readily transduce dividing and non-dividing cells. The integration frequency of adenoviral genome into host DNA is very low (Harui et al., 1999), and engineered replication deficient adenoviruses enhance biosafety. Many adenoviruses, however, elicit immune responses from the patient, which excludes them from
In general, viral gene transfer is highly efficient. Synovial cells can be transduced
4.6. Non-viral gene transfer
Non-viral gene transfer delivers plasmid DNA into the target cells with selected chemical and physical methods. In general, non-viral methods are less elaborate than the generation of transduction viruses. All non-viral methods achieve transient transfection (Welter et al., 2004).
The most common method uses non-ionic or cationic lipids to form DNA-lipid particles. These particles are taken up by the cell and transcribed after transfer into the nucleus. Several compounds are available, which transfect cells with variable efficiencies (Madry et al., 2000). Many protocols for
|Retrovirus||Low transduction efficiency ||Evans et al., 2005|
|Lentivirus||High transduction efficiency of dividing and non-dividing cells, integrating||E. Gouze et al., 2002|
|Adenovirus||Immunogenic, high transduction efficiency||Ghivizzani et al., 1998|
|AAV||Moderate transduction efficiency ||Jorgensen & Apparailly, 2010|
|Lipofection||Cytotoxic, varying transfection|
efficiency, low cost
|Madry et al., 2005|
|Electroporation||Efficient, high equipment costs||Welter et al., 2004|
|Matrix bound DNA||Long lasting, low transfection efficiency||Capito & Spector, 2007|
5. Tissue-engineered scaffolds for ACT
In the context of OA, repair of cartilage surface defects through biological regeneration and transplantation of various tissues or cells have been investigated (Goehring et al., 2010; Stoop, 2008). The technology of scaffold-free ACT pioneered by Brittberg and colleagues has been widely applied to repair small cartilage lesions. Herein, a biopsy is taken from non-weight-bearing regions of cartilage; the chondrocytes are enzymatically extracted, expanded in monolayer culture, and then injected beneath a periosteal flap sutured over the cartilage lesion (Brittberg et al., 1994). This strategy has been used to treat thousands of patients worldwide and offers a transient but practical solution for cartilage repair.
Porous 3-dimensional scaffolds are increasingly used to facilitate cellular attachment and at the same time provide superior mechanical properties. This technique is particularly useful given the lack of cell retention when cell suspensions are directly transplanted at the cartilage defect site. It also reduces potential donor site morbidity associated with procedures that utilize a periosteal flap to increase cellular retention (Brittberg et al., 1994). A wide range of materials have been produced to serve as scaffolds for cartilage repair. Generally they can be classified into three categories: natural, synthetic and biosynthetic materials (Goehring et al., 2010; Langer & Tirrell, 2004; Stoop, 2008). In the following paragraphs, we will highlight some of the important scaffolds from these categories.
5.1. Natural scaffold materials
Natural materials are composed of native biocompounds which mimick the natural surface for cell adhesion and maintain the required physiological environment. In addition, these materials (i) are non-toxic, (ii) follow a physiological biodegrading mechanism and (iii) are used to produce scaffolds for cartilage tissue-engineering (Hunziker, 2002; Stoop, 2008). Collagen-based biomaterials are widely used in clinical practice and have been employed as carriers for chondrocytes (Wakitani et al., 1998) and mesenchymal stem cells (MSCs) (Im et al., 2001). Collagen type I hydrogels resemble hyaline cartilage. They are biodegradable, elicit no inflammation and can be metabolized by MSCs through the action of endogenous collagenases. Rat-tail extracted, collagen type I has been recently developed to construct scaffolds termed cartilage regeneration system (CaReS; Amedrix, Esslingen, Germany). It has been reported that patellofemoral transplantation of CaReS scaffolds for two years showed a significant improvement in cartilage repair in patients (Andereya et al., 2007) resulting in complete defect filling with superior quality repair tissue (Welsch et al., 2010).
Both fibrinogen and its polymer fibrin have been shown to play major roles in healing osteochondral defects (Shapiro et al., 1993), but owing to the exceedingly high concentrations and protein densities, the glue impeded rather than facilitated cell invasion, thus limiting its use (Brittberg et al., 1994). Hyaluronic acid is a non-sulphated glycosaminoglycan (GAG) that makes up a large part of cartilage extracellular matrix. In its unmodified form, it has a high biocompatibility and plays an important role in determining the biophysical microenvironment for chondrocyte growth and proliferation (Poole et al., 1990).
Cell-seeded agarose hydrogels enhance the matrix elaboration upon dynamic deformational loading (Häuselmann et al., 1994). Despite its suitability for implantation, the non-degradable nature of the gel limits its application in tissue-engineering. Alginate, a naturally derived polysaccharide gel, has been successfully shown to support cell retention and the chondrocytic phenotype by maintaining cell shape through encapsulation (Guo et al., 1989; Häuselmann et al., 1994; Rai et al., 2009). On the other hand, its inferior biomechanical properties as well as concerns over its immunogenicity have raised biocompatibility issues (Kulseng et al., 1999). Alginates are easy to use and suitable for the repair of small cartilage defects but fragile during surgery.
5.2. Synthetic scaffold materials
Many synthetic scaffolds commonly used in cartilage tissue-engineering are fabricated using poly(α-hydroxy acid) polymers such as poly-L-lactide, polyglycolic acid and their copolymers poly-DL-lactide-co-glycolide and poly-є-caprolactone (Li et al., 2006; Nöth et al., 2002). They offer optimal fibre diameter, pore size, degradation time and reproducibility in production. The major advantages associated with the use of synthetic polymers are their design flexibility and elimination of disease transmission. Disadvantages of some synthetic polymers are the potential increase in local pH resulting from acidic degradation products, excessive inflammatory responses and poor clearance and chronic inflammation associated with these high molecular weight polymers (Stoop, 2008).
5.3. Biosynthetic scaffold materials
In recent years, a wide array of novel biosynthetic materials has been developed based on natural materials such as silk or cellulose and synthetic materials such as poly(1,8-octanediol citrate) or poly(ether ester) copolymer scaffolds. In addition, numerous attempts have been sought to optimize scaffold properties by combining several different materials. For example, scaffolds have been produced from gelatine, hyaluronic acid and chondroitin-6-sulphate and mixed with fibrin glue or polylactic-co-glycolic acid. To support bone as well as cartilage formation, hydroxyapatite was combined with chitosan to produce scaffolds that allow the treatment of osteochondral defects. Conversely, most of these developments show promise for future clinical application, so far they have mainly been investigated using
6. Obstacles and challenges in clinical application of gene therapy
Gene therapy for OA has been described extensively for the last twenty years and a large body of impressive preclinical safety and efficacy information has been documented (Bandara et al., 1992; Trippel et al., 2004). Despite this fact, only a few clinical trials of this therapeutic strategy have been conducted mainly due to scientific, technological, financial and sociological hurdles (Evans et al., 2011). A single phase II study has been reported recently and this slow pace indicates the unlikelihood of gene therapy to become clinically available in the near future (Mease et al., 2010). One of the most serious reason for the current slow progress in gene therapy research in OA (and RA) lies in the widespread public scepticism with anything relating to genes. The term gene is simply not understood by the average citizen and any genetic intervention in research has a priori a negative connotation. Fitting with this general attitude, regulatory bodies demand extremely hard safety precautions with any genetic intervention with patients which leads to an explosion of cost and duration for the development of these very promising therapies.
Nonetheless, this should not disappoint gene therapy researchers. Despite its slow progress, gene therapy promises to fulfil unmet needs in the treatment of OA and allied joint disorders and therefore has a bright future in the long run. It will eventually offer a focussed, local and perhaps personalized therapy avenue which may well cover the non-responders to the conventional treatment of joint disorders which in the case of RA amount to a substantial percentage (Gibbons & Hyrich, 2009). Furthermore, by applying local gene therapy it will certainly be possible to avoid the widely observed side-effects that occur with the present therapeutics.
Another leading challenge facing gene therapy today is the improvement of current vectors and this area continues to be another limiting factor in gene therapy applications. Even in the field of viral vectors, attempts have been made to combine their application with immunomodulating agents (Ikeda et al., 2000), still obvious problems exist with this approach (Zhou et al., 2004). Similarly, in the area of non-viral gene transfer, researchers are generating new transfection methods/strategies with a number of new products becoming commercially available every year (Donkuru et al., 2010; Haag et al., 2009; Madeira et al., 2011). Yet, an ideal agent that satisfies the requirements for application with the relevant target cells for OA gene therapy is not in sight.
Although the tissue-engineering scaffolds described above are becoming increasingly popular due to the high standards of cellular attachment and mechanical stability, their role in a pro-inflammatory environment in arthritic condition raises some doubts and has not been completely evaluated. An effective therapy of OA in the context of inflammation, however, may be achieved through genetic modification of suitable target cells present in the scaffolds to deliver therapeutic transgenes to the site of disease. Below we elaborate on the choice of cells that can be utilized in this approach and on the question which are the best vehicles for gene delivery mechanism as well as the type of scaffolds for engineering cartilage defects.
7. Controlled expression from “Smart Transplants”
As we all know that the conventional gene therapy has many potential limitations and therefore the need of customized gene therapy arises. The customized form of gene therapy could be defined as a therapy in which autologous cells are genetically modified by species-specific genes under the control of endogenous and disease-responsive elements and made clinically applicable by seeding in the scaffolds. As these scaffolds harbour cells that deliver therapeutic proteins in a fine-tuned manner to the defect site based on the severity of inflammation in the joint, we termed them smart transplants. Each component of smart transplants has been summarized below and is depicted in Figure 2.
7.1. Selection of genes for OA gene therapy
Though various biological factors have been independently identified as necessary for reducing inflammation or promoting regeneration in the diseased joint, the most promising therapeutic agents are those that modulate the activities of the pro-inflammatory cytokines IL-1β and TNF (Fukui et al., 2003; M.B. Goldring, 1999; Martel-Pelletier et al., 1999). Several (anti-inflammatory) agents have been tested that suppress the production of pro-inflammatory mediators (Fernandes et al., 2002). Among these IL-4 (Woods et al., 2001), IL-10 (Amos et al., 2006), and IL-13 (Jovanovic et al., 1998) are of utmost significance in the context of OA. IL-4 compared to IL-10, has a higher potential to inhibit IL-1β (Rachakonda et al., 2008a, 2008b) and only IL-4 (not IL-10) can induce the production of IL-1Ra (Relic et al., 2001). Further, IL-4 can antagonize the effects of TNF by inducing down-regulation and shedding of both forms of TNF receptors while IL-13 failed to produce such effects (Manna & Aggarwal 1998) and unlike IL-4, it does not appear to directly regulate the growth of TH2-type cells (Chomarat & Banchereau, 1998).
OA – particularly in its later stages – is characterized by inflammation and catabolism going side by side (M.B. Goldring & S.R. Goldring, 2007; Pelletier et al., 2001). Therefore, simultaneous expression of both anti-inflammatory and regenerative (anabolic) genes should be taken into consideration. One of the main anabolic mediators, which naturally aids in the protection of cartilage from regular wear and tear, is insulin-like growth factor-1 (IGF-1). IGF-1 is known to maintain homeostasis in articular cartilage by stimulating the synthesis of cartilage matrix proteins noted by an increased production of aggrecan and type II collagen (Manning et al., 2010). IL-4 and IGF-1 would offer a more complete therapy to combat the different aspects of the disease. We consider the dual expression of both proteins and surmise that an effective therapy should comprise the expression of both anti-inflammatory cytokines and cartilage anabolic factors to counteract the effects of catabolic mediators.
7.2. Selection of non-viral vectors
The most worrisome weakness of gene therapy is that many of the immunological defence systems which normally tackle wild-type infections are activated against the vectors and new transgene products might be recognized as foreign. In the past, great advances have been made to create new systems for the efficient production of gene-deleted less immunogenic vectors. These include the improvements such as expansion of the repertoire of vector tropisms and the evasion of pre-existing immune responses through the development of alternative viral serotypes (Hill et al., 1999; Thomas et al., 2003). Non-viral gene delivery is potentially safer than virus-mediated delivery with the exception of a few promising applications, such as vaccines. However, non-viral systems are, at the present, limited by their relatively low transfer efficiency (Thomas et al., 2003). Nevertheless, we prefer the use of non-viral vectors because of their higher safety level.
There is still a tremendous amount of work to be done in gene therapy research. We have encountered many obstacles so far, and will probably encounter more, but these obstacles are not insurmountable. By continuing to identify and address potential hurdles and by maintaining a strong focus on improving vectors and delivery protocols, gene therapy will eventually play a significant role in the treatment of severe inflammatory joint diseases.
7.3. Selection of suitable target cells
The most obvious source for cells that can regenerate cartilage is the tissue itself. Chondrocytes are the cells which reside within and retain and remodel this tissue (M.B. Goldring, 2006). They represent a homogenous population with limited (cell) number and tend to rapidly de-differentiate upon expansion
7.4. Regulation of gene expression
Most gene therapy protocols involve constitutive delivery of therapeutic genes due to the transient nature of expression. In such instances, efficient gene transfer, expression, or stability have encountered limitations in preclinical and clinical applications mainly due to pleiotropic effects of the inducer, low-level basal expression and toxicity of the inducing agents. However, a non-toxic regulation of transgene expression may offer an effective means to control the expression levels of proteins with a narrow therapeutic index such as cytokines and hormones. Obviously, it would be most desirable to control the expression of therapeutic proteins in a disease-dependent manner. This would add considerably to the safety level of the gene therapy application. Incidentally, constitutive over-expression of transgenes typically would lead to detrimental effects under disease conditions. Therefore, regulation of gene expression is warranted. We have previously designed and reported a self-limiting promoter construct that expresses an anti-inflammatory gene only in the presence of inflammation (Patent: PCT/EP 2008/061408 published as US-2010-0255572-A1). The use of this construct for the expression of anti-inflammatory genes allows the production of a therapeutic gene product that is controlled by the severity of the disease. The effectiveness of this promoter construct for combating inflammation makes it a suitable candidate for the development of a new local gene therapy strategy for the treatment of OA (Rachakonda et al., 2008a). Furthermore, the ability to effectively control gene expression should also facilitate gene therapy studies because it will permit the expression of therapeutic genes and subsequently proteins to be regulated within the host. Thus, the application of inflammation-regulated therapeutic gene expression in arthritis conditions increases the efficiency of gene therapy by self-limiting the transgene.
Such elegant approaches have been adopted by applying disease-regulated promoters in a number of published reports (Cui et al., 2006; Godbey & Atala, 2003; Meynier de Salinelles et al., 2002; Miagkov et al., 2002; Rygg et al., 2001; Uhlar et al., 1997; Varley et al., 1995). Elements of the IL-1 and IL-6 promoter or of the COX-2 promoter, which are activated under inflammatory conditions, should up-regulate the transcription of transgenes such as IL-4 during acute OA and decrease expression rates after cessation of inflammation (Geurts et al., 2007; Rachakonda et al., 2008a). These self-regulating approaches may lead to safer stable transplants, which smartly react to the OA status of the joint.
7.5. Selection of suitable scaffolds
The selection of suitable scaffolds represents an important step to restore the damaged cartilage. Therefore, the selection of a suitable matrix composition may stabilize the transplant and support the regenerative process. Furthermore, the delivery of therapeutic genes will be more effective in a matrix that provides suitable protection, since the target cell population must often be exposed to factors throughout the entire course of repair, or at least for an extended period of time. An increased retention at treatment sites could also enable regenerative tissue-forming cells to migrate to the area of injury and to proliferate and differentiate. In addition, the materials should be biodegradable and remodel as the new cartilage forms and replaces the original construct. These matrix materials could be combined with other types of carriers, which release active factors into the environment as they disperse or are degraded without providing any matrix function.
In this regard, the matrix should be non-toxic, non-adhesive and non-stimulatory for inflammatory cells such as lymphocytes, macrophages and neutrophils. Furthermore, any matrix material needs to be non-immunogenic since immunological attack to this material (then serving as an antigen) would be detrimental to tissue regeneration. The topography and material properties of natural scaffolds should also support the differentiation of MSCs. Finally, the scaffolds should be easy to handle during surgery thereby allowing the fixation of the transplant into the implant site with ease. From our experience rat tail collagen-based scaffolds have a number of advantages along these lines.
8. Preliminary data on “Smart Transplants”
It has been shown previously that chondrocytes in scaffolds are susceptible to inflammatory mediators (Kuroki et al., 2005; Rai et al., 2008). This scenario indirectly raises a question on the validity of ACT into cartilage lesions surrounded by progressive inflammation (Hennerbichler et al., 2008). In order to address this problem, we validated the inducible expression of IL-4 in chondrocytes (Rachakonda et al., 2008a, 2008b) and in a chondrocyte-based, 3-dimensional inflammation model (Rai et al., 2011). The main objective was to examine whether IL-4 produced within scaffolds can down-regulate inflammation and recoup extracellular matrix synthesis in the face of inflammation. We believe that this was the first study of its type to assess the use of cytokine-therapy devoid of viral vectors in a 3-dimensional
Mature canine chondrocytes were conditioned through transient transfection using pcDNA3.1.IL-4 (constitutive) or pCOX-2.IL-4 (cytokine-responsive) plasmids. Conditioned cells were seeded in alginate microspheres and rat-tail collagen type I matrix (CaReS) to generate two types of tissue-engineered scaffolds, alginate beads and CaReS-matrices containing engineered chondrocytes. Inflammation was induced in the packed chondrocytes through addition of recombinant IL-1β plus TNF into the culture medium. Harvested cells and culture media were analysed by various assays to monitor the anti-inflammatory and regulatory (anabolic) properties of IL-4 (Rai et al., 2011).
The data obtained proved that IL-4 was expressed at sufficient levels to effectively down-regulate inflammation in both types of scaffolds. This indicated that both scaffolds containing conditioned chondrocytes allowed unrestricted diffusion of cytokines in and out of the cells and through the matrix network into the surrounding culture medium. It was shown that IL-4 was able to successfully down-regulate several pro-inflammatory cytokines, matrix degrading enzymes and various catabolic end products such as nitric oxide and prostaglandin. Further, the biochemical assessment of the levels of collagen and sulphated GAG also indicated the anabolic net effect of IL-4 on chondrocytes.
One of the important characteristics of our approach is the ability of the pCOX-2.IL-4 construct to deliver the therapeutic gene (in this case IL-4) only upon stimulation with exogenous IL-1β and TNFα. Thereby the expression of IL-4 is controlled through the severity of inflammation as defined by the presence of pro-inflammatory cytokines (Figure 3).
Since chondrocytes were conditioned by transfection prior to the generation of scaffolds, we coined a new term for this type of approach: ACCT (autologous conditioned cell therapy). Thus, therapeutic expression only occurs in a clearly defined condition, i.e. when the “conditioned” cells present in the scaffold “sense” inflammation in their surroundings.
We have also worked on the dual expression of IL-4 and IGF-1 in chondrocytes (Manning et al., 2010) because this approach potentially offers a more complete therapy to combat the different aspects of OA. The use of multiple genes could better alleviate the signs and symptoms characteristic for the disease process. Extension of this strategy to other suitable genes or combination of genes could in the future provide a better outlook to effectively heal OA. Ideally, if the cytokine-responsive matrices described above do work in the patient as they do
Without any doubt, future therapy trials will have to occur to validate this novel approach.
9. Summary and future perspectives
OA affects a huge population of elderly. Recent progress in the understanding of OA pathophysiology has facilitated the development of therapeutic strategies aimed specifically at effectively retarding the disease process. Unfortunately most therapeutic efforts appear to have been directed either to temporal pain relief, or to the repair of OA-related cartilage lesions. As a final resort total joint replacement through surgery will be necessary. Gene therapy still has many pitfalls. The use of viral vectors and the unrestricted expression of transgenes are still subject to unanswered safety questions posed by the regulatory authorities. Nevertheless, it is tempting to speculate that an effective stimulation of cartilage regeneration paralleled by an inhibition of inflammation must be the key objectives of new therapeutic approaches. The negative impact of gene therapy can be overcome if it is suitably improved in each of its components. The first and foremost component of gene therapy is the vector. Viral vectors can be replaced by non-viral vectors regardless of which therapeutic genes they orchestrate and what expression levels may be achieved. Further, the promoter placed upstream of the therapeutic gene should be disease-dependent. In OA it should be inflammation dependent – like a COX-2 promoter that is always up-regulated when IL-1β and TNFα are up in the joint. Because IL-1β and TNFα drive OA progression and cartilage degradation, they become an important target in OA. Thus, genes like IL-4 and IGF-1 not only can coup with these pro-inflammatory cytokines, they also help to rebuild the normal cartilage tissue architecture.
For the delivery of suitable therapeutic genes in a non-viral approach, the selection of target cells is very important. Nature has provided the cartilage with only one cell type i.e. chondrocytes. In our opinion they are the best choice for transplantation in cartilage-related problems. But owing to their rapid differentiation into fibroblasts and lower cell number from a limited area of cartilage, stem cells may offer an important alternative in the future. Cell transplantation will require assembly for their implantation in the joint for which a wide-array of scaffolds is available. Whenever conditioned cells are involved that produce therapeutic proteins the best scaffolds are those that provide free diffusion of biological agents in and out.
To this end, we have established the applicability and usefulness of cell-seeded scaffolds
The future of gene therapy as a viable medical application can be summarized in the words phrased by French Anderson in 1998: “Despite our present lack of knowledge, gene therapy will almost certainly revolutionize the practice of medicine over the next 25 years. In every field of medicine, the ability to give the patient therapeutic genes offers extraordinary opportunities to treat, cure and ultimately prevent a vast range of diseases that now plague mankind”(Anderson, 1998). Impressive progress has been made thus far, but nevertheless it seems we need the remaining 12 years to see where we stand.
Abramson S. B. Yazici Y. 2006Biologics in Development for Rheumatoid Arthritis: Relevance to Osteoarthritis. , 58 2(May 2006), 212 225, 0016-9409X
Adachi N. Sato K. Usas A. Fu F. H. Ochi M. Han C. W. Niyibizi C. Huard J. 2002Muscle-derived, Cell-based Gene Therapy for Treatment of Full-thickness Articular Cartilage Defects. Journal of Rheumatology, 29 9(September 2002), 1920 1930, 0031-5162X
Amos N. Lauder S. Evans A. Feldmann M. Bondeson J. 2006Adenoviral Gene Transfer into Osteoarthritis Synovial Cells using the Endogenous Inhibitor IB Reveals that most, but not all, Inflammatory and Destructive Mediators are NFB Dependent. , 45 10(October 2006), 1201 1209, 1462-0324
Andereya S. Maus U. Gavenis K. Müller-Rath R. Miltner O. Mumme T. Schneider U. 2007First Clinical Experiences with a Novel 3D Collagen Gel (CaReS) for the Treatment of Focal Cartilage Defects in the Knee. 144 3(May-June 2007), 272 280, 0044-3220
Anderson W. F. 1998Human Gene Therapy. 392 S6679(April 1998), 25 30, 1476-4687
Bandara G. Robbins P. D. Georgescu H. I. Mueller G. M. Glorioso J. C. Evans C. H. 1992Gene Transfer to Synoviocytes: Prospects for Gene Treatment of Arthritis. 11 3(April 1992), 227 231, 1044-5498
Brittberg M. Lindahl A. Nilsson A. Ohlsson C. Isaksson O. Peterson L. 1994Treatment of Deep Cartilage Defects in the Knee with Autologous Chondrocyte Transplantation. , 331 14(October 1994), 889 895, 0028-4793
Buckwalter J. A. Martin J. A. Brown T. D. 2006Perspectives on Chondrocyte Mechanobiology and Osteoarthritis. , 43 3-4, (September 2006), 603 609, 0000-6355X
Capito R. M. Spector M. 2007Collagen Scaffolds for Non-viral IGF-1 Gene Delivery in Articular Cartilage Tissue-engineering. 14 9(May 2007), 721 732, 0969-7128
Celiker M. Y. Ramamurthy N. Xu J. W. Wang M. Jiang Y. Greenwald R. Shi Y. E. 2002Inhibition of Adjuvant-induced Arthritis by Systemic Tissue Inhibitor of Metalloproteinases-4 Gene Delivery. , 46 12(December 2002), 3361 3368, 0004-3591
Chomarat P. Banchereau J. 1998Interleukin-4 and Interleukin-13: Their Similarities and Discrepancies. 17 1-4, (January 1998), 1 52, 0883-0185
Clouet J. Vinatier C. Merceron C. Pot-vaucel M. Maugars Y. Weiss P. Grimandi G. Guicheux J. 2009From Osteoarthritis Treatments to Future Regenerative Therapies for Cartilage. , 14 19-20, (October 2009), 913 925, 1359-6446
Cucchiarini M. Madry H. 2005Gene Therapy for Cartilage Defects. , 7 12(December 2005), 1495 1509, 0109-9498X
Cucchiarini M. Thurn T. Weimer A. Kohn D. Terwilliger E. F. Madry H. 2007Restoration of the Extracellular Matrix in Human Osteoarthritic Articular Cartilage by Over-expression of the Transcription Factor SOX-9. , 56 1(January 2007), 158 167, 0004-3591
Cui X. Yang S. C. Sharma S. Heuze-Vourc’h N. Dubinett S. M. 2006IL-4 Regulates COX-2 and PGE2 Production in Human Non-small Cell Lung Cancer. 343 4(May 2006), 995 1001, 0000-6291X
Di Cesare P. E. Frenkel S. R. Carlson C. S. Fang C. Liu C. 2006Regional Gene Therapy for Full-thickness Articular Cartilage Lesions using Naked DNA with a Collagen Matrix. , 24 5(May 2006), 1118 1127, 0736-0266
Donkuru M. Badea I. Wettig S. Verrall R. Elsabahy M. Foldvari M. 2010Advancing Nonviral Gene Delivery: Lipid- and Surfactant-based Nanoparticle Design Strategies. , 5 7(September 2010), 1103 1127, 1743-5889
Dougados M. 2006Symptomatic Slow-acting Drugs for Osteoarthritis: What are the Facts? , 73 6(December 2006), 606 609, 0129-7319X
Evans C. H. Robbins P. D. 1994The Interleukin-1 Receptor Antagonist and its Delivery by Gene Transfer. , 4 1(Spring 1994), 9 15, 1052-8040
Evans C. H. Ghivizzani S. C. Oligino T. A. Robbins P. D. 2001Future of Adenoviruses in the Gene Therapy of Arthritis. , 3 3(n.d. 2001), 142 146, 1465-9905
Evans C. H. Gouze J. N. Gouze E. Robbins P. D. Ghivizzani S. C. 2004Osteoarthritis Gene Therapy. , 11 4(February 2004), 379 389, 0969-7128
Evans C. H. Robbins P. D. Ghivizzani S. C. Wasko M. C. Tomaino M. M. Kang R. Muzzonigro T. A. Vogt M. Elder E. M. Whiteside T. L. Watkins S. C. Herndon J. H. 2005Gene Transfer to Human Joints: Progress toward a Gene Therapy of Arthritis. , 102 24(June 2005), 8698 8703, 0027-8424
Evans C. H. Ghivizzani S. C. Robbins P. D. 2009Gene Therapy of the Rheumatic Diseases: 1998 to 2008. , 11 1(January 2009), 209 1478-6354
Evans C. H. Ghivizzani S. C. Robbins P. D. 2011Getting Arthritis Gene Therapy into the Clinic. , 7 4(April 2011), 244 249, 1759-4790
Fernandes J. C. Tardif G. Martel-Pelletier J. Lascau-Coman V. Dupuis M. Moldovan F. Sheppard M. Krishnan B. R. Pelletier J. P. 1999Transfer of Interleukin-1 Receptor Antagonist Gene in Osteoarthritic Rabbit Knee Joints. Prevention of Osteoarthritis Progression. American Journal of Pathology, 154 4(April 1999), 1159 1169, 0002-9440
Fernandes J. C. Martel-Pelletier J. Pelletier J. P. 2002The Role of Cytokines in Osteoarthritis Pathophysiology. 39 1-2, (January 2002), 237 246, 0000-6355X
Frisbie D. D. Ghivizzani S. C. Robbins P. D. Evans C. H. Mc Ilwraith C. W. 2002Treatment of Experimental Equine Osteoarthritis by Delivery of the Equine Interleukin-1 Receptor Antagonist Gene. Gene Therapy, 9 1(January 2002), 12 20, 0969-7128
Fukui N. Zhu Y. Maloney W. J. Clohisy J. Sandell L. J. 2003Stimulation of BMP-2 Expression by Pro-inflammatory Cytokines IL-1 and TNFα in Normal and Osteoarthritic Chondrocytes. 85 3(August 2003), 59 66, 1535-1386
Gelse K. von der Mark. K. Aigner T. Park J. Schneider H. 2003Articular Cartilage Repair by Gene Therapy using Growth Factor-producing Mesenchymal Cells. , 48 2(February 2003), 430 441, 0004-3591
Geurts J. Arntz O. J. Bennink M. B. Joosten L. A. van den Berg. W. B. van de Loo F. A. 2007Application of a Disease-regulated Promoter is a Safer Mode of Local IL-4 Gene Therapy for Arthritis. , 14 23(December 2007), 1632 1638, 0969-7128
Ghivizzani S. C. Lechman E. R. Tio C. Mulé K. M. Chada S. Mc Cormack J. E. Evans C. H. Robbins P. D. 1997Direct Retrovirus-mediated Gene Transfer to the Synovium of the Rabbit Knee: Implications for Arthritis Gene Therapy. , 4 9(September 1997), 977 982, 0969-7128
Ghivizzani S. C. Lechman E. R. Kang R. Tio C. Kolls J. Evans C. H. Robbins P. D. 1998Direct Adenovirus-mediated Gene Transfer of Interleukin-1 and Tumour Necrosis Factor-alpha Soluble Receptors to Rabbit Knees with Experimental Arthritis hasLocal and Distal Anti-arthritic Effects. 95 8(April 1998), 4613 4618, 0027-8424
Gibbons L. J. Hyrich K. L. 2009Biologic Therapy for Rheumatoid Arthritis: Clinical Efficacy and Predictors of Response. 23 2(April 2009), 111 124, 1173-8804
Godbey W. T. Atala A. 2003Directed Apoptosis in COX-2-overexpressing Cancer Cells through Expression-targeted Gene Delivery. 10 17(August 2003), 1519 1527, 0969-7128
Godfrey D. R. 2005Osteoarthritis in Cats: ARetrospective Radiological Study. 46 9(September 2005), 425 429, 0022-4510
Goehring A. R. Lübke C. Kaps C. Häupl T. Pruss A. Perka C. Sittinger M. Ringe J. 2010Tissue-engineered Cartilage of Porcine and Human Origin as In Vitro Test System in Arthritis Research. , 26 4(July-August 2010), 1116 1125, 1520-6033
Goldring M. B. 1999The Role of Cytokines as Inflammatory Mediators in Osteoarthritis: Lessons from Animal Models. 40 1(January 1999), 1 11, 0300-8207
Goldring M. B. 2001Anticytokine Therapy for Osteoarthritis. , 1 5(September 2001), 817 829, 1471-2598
Goldring M. B. 2006Update on the Biology of the Chondrocyte and New Approaches to Treating Cartilage Diseases. , 20 5(October 2006), 1003 1025, 1521-6942
Goldring M. B. Goldring S. R. 2007Osteoarthritis. , 21 3(December 2007), 626 634, 0021-9541
Gouze E. Pawliuk R. Pilapil C. Gouze J. N. Fleet C. Palmer G. D. Evans C. H. Leboulch P. Ghivizzani S. C. 2002Gene Delivery to Synovium by Lentiviral Vectors. Molecular Therapy, 5 4(April 2002), 397 404, 1525-0016
Gouze E. Gouze J. N. Palmer G. D. Pilapil C. Evans C. H. Ghivizzani S. C. 2007Transgene Persistence and Cell Turnover in the Diarthrodial Joint: Implications for Gene Therapy of Chronic Joint Diseases. , 15 6(June 2007), 1114 1120, 1525-0016
Gouze J. N. Gouze E. Palmer G. D. Kaneto H. Ghivizzani S. C. Grodzinsky A. J. Evans C. H. 2004Adenovirus-mediated Gene Transfer of Glutamine: Fructose-6-phosphate Amidotransferase Antagonizes the Effects of Interleukin-1β on Rat Chondrocytes. , 12 3(March 2004), 217 224, 1063-4584
Grossin L. Cournil-Henrionnet C. Mir L. M. Liagre B. Dumas D. Etienne S. Guingamp C. Netter P. Gillet P. 2003Direct Gene Transfer into Rat Articular Cartilage by Electroporation. The FASEB Journal, 17 8(May 2003), 829 835, 0892-6638
Grossin L. Cournil-Henrionnet C. Pinzano A. Gaborit N. Dumas D. Etienne S. Stoltz J. F. Terlain B. Netter P. Mir L. M. Gillet P. 2006Gene Transfer with HSP 70 in Rat Chondrocytes Confers Cytoprotection and during Experimental Osteoarthritis. The FASEB Journal, 20 1(January 2006), 65 75, 0892-6638
Guo J. Jourdian G. Maccallum D. K. 1989Culture and Growth Characteristic of Chondrocytes Encapsulated in Alginate Beads. 19 2-4, (n.d. 1989), 277 285, 1607-8438
Haag J. Voigt R. Soeder S. Aigner T. 2009Efficient Non-viral Transfection of Primary Human Adult Chondrocytes in a High-throughput Format. , 17 6(June 2009), 813 817, 1063-4584
Habib G. S. Saliba W. Nashashibi M. 2010Local Effects of Intra-articular Corticosteroids. , 29 4(April 2010), 347 356, 0770-3198
Harui A. Suzuki S. Kochanek S. Mitani K. 1999Frequency and Stability of Chromosomal Integration of Adenovirus Vectors. , 73 7(July 1999), 6141 6146, 0002-2538X
Häuselmann H. J. Fernandes R. J. Mok S. S. Schmid T. M. Block J. A. Aydelotte M. B. Kuettner K. E. Eugene J. M. Thonar E. J. 1994Phenotypic Stability of Bovine Articular Chondrocytes after Long-term Culture in Alginate Beads 107 1(January 1994), 17 27, 1477-9137
Heinegård D. Saxne T. 2011The Role of the Cartilage Matrix in Osteoarthritis. , 7 1(January 2011), 50 56, 1759-4790
Hennerbichler A. Rosenberger R. Arora R. Hennerbichler D. 2008Biochemical, Biomechanical and Histological Properties of Osteoarthritic Porcine Knee Cartilage: Implications for Osteochondral Transplanation. 128 1(January 2008), 61 70, 0936-8051
Hidaka C. Goodrich L. R. Chen C. T. Warren R. F. Crystal R. G. Nixon A. J. 2003Acceleration of Cartilage Repair by Genetically Modified Chondrocytes Over-expressing Bone Morphogenetic Protein-7. , 21 4(July 2003), 573 583, 0736-0266
Hill C. L. Bieniasz P. D. Mc Clure M. O. 1999Properties of Human Foamy Virus Relevant to its Development as a Vector for Gene Therapy. 80 8(August 1999), 2003 2009, 0022-1317
Hotz-Behofsits C. M. Walley M. J. Simpson R. Bjarnason I. T. 2003COX-1, COX-2 and the Topical Effect in NSAID-induced Enteropathy. 11 4n.d. 2003), 363 370, 0925-4692
Hsieh J. L. Shen P. C. Shiau A. L. Jou I. M. Lee C. H. Wang C. R. Teo M. L. Wu C. L. 2010Intra-articular Gene Transfer of Thrombospondin-1 Suppresses the Disease Progression of Experimental Osteoarthritis. , 28 10(October 2010), 1300 1306, 0736-0266
Hunziker E. B. 2002Articular Cartilage Repair: Basic Science and Clinical Progress. A Review of the Current Status and Prospects. 10 6(June 2002), 432 463, 1063-4584
Ikeda K. Wakimoto H. Ichikawa T. Jhung S. Hochberg F. H. Louis D. N. Chiocca E. A. 2000Complement Depletion Facilitates the Infection of Multiple Brain Tumors by an Intravascular, Replication-Conditional Herpes Simplex Virus Mutant. 74 10(May 2000), 4765 4775, 0002-2538X
Im G. I. Kim D. Y. Shin J. H. Hyun C. W. Cho W. H. 2001Repair of Cartilage Defect in the Rabbit with Cultured Mesenchymal Stem Cells from Bone-marrow. 83 2(March 2001), 289 294, 0030-1620X
Innes J. F. Clegg P. 2010Comparative Rheumatology: What can be Learnt from Naturally Occurring Musculoskeletal Disorders in Domestic Animals? , 49 6(June 2010), 1030 1039, 1462-0324
Johnston S. A. 1997Osteoarthritis. Joint Anatomy, Physiology, and Pathobiology. 27 4(July 1997), 699 723, 0195-5616
Jorgensen C. Apparailly F. 2010Prospects for Gene Therapy in Inflammatory Arthritis. , 24 4(August 2010), 541 552, 1521-6942
Jovanovic D. Pelletier J. P. Alaaeddine N. Mineau F. Geng C. Ranger P. Martel-Pelletier J. 1998Effect of IL-13 on Cytokines, Cytokine Receptors and Inhibitors on Human Osteoarthritis Synovium and Synovial Fibroblasts. , 6 1(January 1998), 40 49, 1063-4584
Kang R. Marui T. Ghivizzani S. C. Nita I. M. Georgescu H. I. Suh J. K. Robbins P. D. Evans C. H. 1997Gene Transfer to Chondrocytes in Full-thickness Articular Cartilage Defects: A Feasibility Study. Osteoarthritis & Cartilage, 5 2(March 1997), 139 143, 1063-4584
Katayama R. Wakitani S. Tsumaki N. Morita Y. Matsushita I. Gejo R. Kimura T. 2004Repair of Articular Cartilage Defects in Rabbits using CDMP1 Gene Transfected Autologous Mesenchymal Cells Derived from Bone Marrow., 43 8(August 2004), 980 985, 1462-0324
Katz J. N. Brandon E. E. Gomoll A. H. 2010Surgical Management of Osteoarthritis. , 62 9(September 2010), 1220 1228, 0215-1464X
Kaul G. Cucchiarini M. Arntzen D. Zurakowski D. Menger M. D. Kohn D. Trippel S. B. Madry H. 2006Local Stimulation of Articular Cartilage Repair by Transplantationof Encapsulated Chondrocytes Over-expressing Human Fibroblast Growth Factor-2(FGF-2) . Journal of Gene Medicine, 8 1(January 2006), 100 111, 0109-9498X
Kulseng B. Skjak-Braek G. Ryan L. Andersson A. King A. Faxvaag A. Espevik T. 1999Transplantation of Alginate Microcapsules: Generation of Antibodies against Alginates and Encapsulated Porcine Islet-like Cell Clusters 67 7(April 1999), 978 984, 1534-0608
Kuroki K. Stoker A. M. Cook J. L. 2005Effects of Proinflammatory Cytokines on Canine Articular Chondrocytes in a Three-dimensional Culture. 66 7(July 2005), 187 196, 0002-9645
Lafeber F. P. van Roy H. L. van der Kraan P. M. van den Berg. W. B. Bijlsma J. W. 1997Transforming Growth Factor-beta Predominantly Stimulates Phenotypically Changed Chondrocytes in Osteoarthritic Human Cartilage. , 24 3(March 1997), 536 542, 0031-5162X
Langer R. Tirrell D. A. 2004Designing Materials for Biology and Medicine. 428 6982(April 2004), 487 492, 1476-4687
Lee K. H. Song S. U. Hwang T. S. Yi Y. Oh I. S. Lee J. Y. Choi K. B. Kim S. J. 2001Regeneration of Hyaline Cartilage by Cell-mediated Gene Therapy using Transforming Growth Factor-β1-producing Fibroblasts. , 12 14(September 2001), 1805 1813, 1043-0342
Li W. J. Jiang Y. J. Tuan R. S. 2006Chondrocyte Phenotype in Engineered Fibrous Matrix is Regulated by Fiber Size. 12 7(July 2006), 1775 1785, 2152-4955
Liao Y. H. Jones S. A. Forbes B. Martin G. P. Brown M. B. 2005Hyaluronan: Pharmaceutical Characterization and Drug Delivery. , 12 6(November-December 2005), 327 342, 1071-7544
Madeira C. Ribeiro S. C. Pinheiro I. S. Martins S. A. Andrade P. Z. da Silva. C. L. Cabral J. M. 2011Gene delivery to human bone marrow mesenchymal stem cells by microporation. , 151 1(January 2011), 130 136, 0168-1656
Madry H. Trippel S. B. 2000Efficient Lipid-mediated Gene Transfer to Articular Chondrocytes. , 7 4(February 2000), 286 291, 0969-7128
Madry H. Padera R. Seidel J. Langer R. Freed L. E. Trippel S. B. Vunjak-Novakovic G. 2002Gene Transfer of a Human Insulin-like Growth Factor 1 cDNA Enhances Tissue-engineering of Cartilage. , 13 13(September 2002), 1621 1630, 1043-0342
Madry H. Cucchiarini M. Terwilliger E. F. Trippel S. B. 2003Recombinant Adeno-associated Virus Vectors Efficiently and Persistently Transduce Chondrocytes in Normal and Osteoarthritic Human Articular Cartilage. , 14 4(March 2003), 393 402, 1043-0342
Madry H. Emkey G. Zurakowski D. Trippel S. B. 2004Over-expression of Human Fibroblast Growth Factor-2 Stimulates Cell Proliferation in an Model of Articular Chondrocyte Transplantation. The Journal of Gene Medicine, 6 2(February 2004), 238 245, 0109-9498X
Madry H. Kaul G. Cucchiarini M. Stein U. Zurakowski D. Remberger K. Menger M. D. Kohn D. Trippel S. B. 2005Enhanced Repair of Articular Cartilage Defects by Transplanted Chondrocytes Over-expressing Insulin-like Growth Factor-1 (IGF-1). Gene Therapy, 12 15(August 2005), 1171 1179, 0969-7128
Manna S. K. Aggarwal B. B. 1998Interleukin-4 Down-regulates both Forms of TumourNecrosis Factor Receptor and Receptor-mediated Apoptosis, NF-kappa B, AP-1, and c-Jun N-terminal Kinase. Comparison with Interleukin-13. 273 50(December 1998), 33333 33341, 0108-3351X
Manning K. Rachakonda P. S. Rai M. F. Schmidt M. F. 2010Co-expression of Insulin-like Growth Factor-1 and Interleukin-4 in an Inflammatory Model. Cytokine, 50 3(June 2010), 297 305, 1043-4666
Martel-Pelletier J. Alaaeddine N. Pelletier J. P. 1999Cytokines and their Role in the Pathophysiology of Osteoarthritis. nce, 4No.D, (October 1999), 694 703, 1093-9946
Martel-Pelletier J. Pelletier J. P. 2007Inflammatory Factors Involved in Osteoarthritis, In: , J. Buckwalter, M. Lotz & J.F. Stolz, (Eds.), 3 13, IOS Press, 978-1-58603-773-4Amsterdam, Netherlands
Mease P. J. Wei N. Fudman E. J. Kivitz A. J. Schechtman J. Trapp R. G. Hobbs K. F. Greenwald M. Hou A. Bookbinder S. A. Graham G. E. Wiesenhutter C. W. Willis L. Ruderman E. M. Forstot J. Z. Maricic M. J. Dao K. H. Pritchard C. H. Fiske D. N. Burch F. X. Prupas H. M. Anklesaria P. Heald A. E. 2010Safety, Tolerability, and Clinical Outcomes after Intra-articular Injection of a Recombinant Adeno-associated Vector Containing a Tumour Necrosis Factor Antagonist Gene: Results of a Phase 1/2 Study. , 37 4(April 2010) 692 703, 1499-2752
Meynier de Salinelles. V. Berenbaum F. Jacques C. Salvat C. Olivier J. L. Béréziat G. Raymondjean M. Massaad C. 2002Design of a Chimeric Promoter induced by Pro-inflammatory Mediators in Articular Chondrocytes. 518 1-3, (May 2002), 67 71, 0014-5793
Miagkov A. V. Varley A. W. Munford R. S. Makarov S. S. 2002Endogenous Regulation of a Therapeutic Transgene Restores Homeostasis in Arthritic Joints. 109 9(May 2002), 1223 1229, 0021-9738
Minas T. Gomoll A. H. Solhpour S. Rosenberger R. Probst C. Bryant T. 2010Autologous Chondrocyte Implantation for Joint Preservation in Patients with Early Osteoarthritis. 468 1(January 2010), 147 157, 0000-9921X
Müller R. D. John T. Kohl B. Oberholzer A. Gust T. Hostmann A. Hellmuth M. Laface D. Hutchins B. Laube G. Veh R. W. Tschoeke S. K. Ertel W. Schulze-Tanzil G. 2008IL-10 Over-expression Differentially Affects Cartilage Matrix Gene Expression in Response to TNF-alpha in Human Articular Chondrocytes. Cytokine, 44 3(December 2008), 377 385, 1043-4666
Nabbe K. C. van Lent P. L. Holthuysen A. E. Sloëtjes A. W. Koch A. E. Radstake T. R. van den Berg. W. B. 2005Local IL-13 Gene Transfer Prior to Immune-complex Arthritis Inhibits Chondrocyte Death and Matrix-metalloproteinase-mediated Cartilage Matrix Degradation Despite Enhanced Joint Inflammation. 7 2(January 2005), R392 R401, 1478-6362
(2002).Engineered Cartilage Constructs Produced by Press-coating Biodegradable Polymer with Human Mesenchymal Stem Cells. Tissue Engineering, Nöth U. Tuli R. Osyczka A. M. Danielson K. G. Tuan R. S. (2002 8 8 1(n.d. 2002), 131 144, 2152-4955
Nöth U. Steinert A. F. Tuan R. S. 2008Technology Insight: Adult Mesenchymal Stem Cells for Osteoarthritis Therapy. , 4 7(July 2008), 371 380, 1745-8382
Park J. Y. Pillinger M. H. Abramson S. B. 2006Prostaglandin E2 Synthesis and Secretion: The Role of PGE2 Synthases. , 119 3(June 2006), 229 240, 1521-6616
Parker D. A. Beatty K. T. Giuffre B. Scholes C. J. Coolican M. R. 2011Articular Cartilage Changes in Patients with Osteoarthritis after Osteotomy. 39 5(May 2011), 0363-5465
Pelletier J. P. Caron J. P. Evans C. Robbins P. D. Georgescu H. I. Jovanovic D. Fernandes J. C. Martel-Pelletier J. 1997Suppression of Early Experimental Osteoarthritis by Interleukin-1 Receptor Antagonist using Gene Therapy. Arthritis & Rheumatism, 40S 6(June 1997), 1012 1019, 0004-3591
Pelletier J. P. Martel-Pelletier J. Abramson S. B. 2001Osteoarthritis, an Inflammatory Disease: Potential Implication for the Selection of New Therapeutic Targets. , 44 6(June 2001), 1237 1247, 0004-3591
Peterson L. Brittberg M. Kiviranta I. Akerlund E. L. Lindahl A. 2002Autologous Chondrocyte Transplantation. Biomechanics and Long-term Durability. 30 1(January-February 2002), 2 12, 0363-5465
Philpott N. J. Thrasher A. J. 2007Use of Non-integrating Lentiviral Vectors for Gene Therapy. , 18 6(June 2007), 483 489, 1043-0342
Pittenger M. F. Mackay A. M. Beck S. C. Jaiswal R. K. Douglas R. Mosca J. D. Moorman M. A. Simonetti D. W. Craig S. Marshak D. R. 1999Multilineage Potential of Adult Human Mesenchymal Stem Cells. 284 5411(April 1999), 143 147, 1095-9203
Plank C. Schillinger U. Scherer F. Bergemann C. Rémy J. S. Krötz F. Anton M. Lausier J. Rosenecker J. 2003The Magnetofection Method: Using Magnetic Force to Enhance Gene Delivery. 384 5(May 2003), 737 747, 0021-9258
Poole C. A. Honda T. Skinner S. J. Schofield J. R. Hyde K. F. Shinkai H. 1990Chondrons from Articular Cartilage (II): Analysis of the Glycosaminoglycans in the Cellular Microenvironment of Isolated Canine Chondrons. 24 3-4, (n.d. 1990), 319 330, 1607-8438
Rachakonda P. S. Rai M. F. Schmidt M. F. 2008aApplication of Inflammation Responsive Promoter for an Arthritis Model. Arthritis & Rheumatism, 58 7(July 2008), 2088 2097, 0004-3591
Rachakonda P. S. Rai M. F. Manning K. Schmidt M. F. 2008bExpression of Canine Interleukin-4 in Canine Chondrocytes Inhibits Inflammatory Cascade through STAT6. , 44 1(October 2008), 179 184, 1043-4666
Rai M. F. Rachakonda P. S. Manning K. Vorwerk B. Brunnberg L. Kohn B. Schmidt M. F. 2008Quantification of Cytokines and Inflammatory Mediators in a Three-dimensional Model of Inflammatory Arthritis. 42 1(April 2008), 8 17, 1043-4666
Rai M. F. Rachakonda P. S. Manning K. Palissa C. Sittinger M. Ringe J. Schmidt M. F. 2009Molecular and Phenotypic Modulation of Primary and Immortalized Canine Chondrocytes in Different Culture Systems. 87 3(December 2009), 399 407, 0034-5288
Rai M. F. Graeve T. Twardziok S. Schmidt M. F. 2011Evidence for Regulated Interleukin-4 Expression in Chondrocyte-scaffolds Under Inflammatory Conditions. (submitted)
Relic B. Guicheux J. Mezin F. Lubberts E. Togninalli D. Garcia I. van den Berg. W. B. Guerne P. A. 2001IL-4 and IL-13, but not IL-10, Protect Human Synoviocytes from Apoptosis. 166 4(February 2001), 2775 2782, 0022-1767
Rygg M. Uhlar C. M. Thorn C. Jensen L. E. Gaughan D. J. Varley A. W. Munford R. S. Göke R. Chen Y. Whitehead A. S. 2001Evaluation of an Enhanced Human Serum Amyloid A (SAA2) Promoter-regulated Soluble TNF Receptor Fusion Protein for Anti-inflammatory Gene Therapy. Scandinavian Journal of Immunology, 53 6(June 2001), 588 595, 1365-3083
Sandell L. J. Aigner T. 2001Articular Cartilage and Changes in Arthritis. An Introduction: Cell Biology of Osteoarthritis. , 3 2(January 2001), 107 113, 1465-9905
Sant S. M. Suarez T. M. Moalli M. R. Wu B. Y. Blaivas M. Laing T. J. Roessler B. J. 1998Molecular Lysis of Synovial Lining Cells by Herpes Simplex Virus-thymidine Kinase Gene Transfer. Human Gene Therapy, 9 18(December 1998), 2735 2743, 1043-0342
Scarpignato C. Hunt R. H. 2010Nonsteroidal Antiinflammatory Drug-related Injury to the Gastrointestinal Tract: Clinical Picture, Pathogenesis, and Prevention. 39 3(September 2010), 433 464, 0889-8553
Shapiro F. Koide S. Glimcher M. J. 1993Cell Origin and Differentiation in the Repair of Full-thickness Defects of Articular Cartilage. 75 4(April 1993), 532 553, 1535-1386
Stoop R. 2008Smart Biomaterials for Tissue-engineering. 39 S1(April 2008), S77 S87, 0020-1383
(2003).Progress and Problems with the Use of Viral Vectors for Gene Therapy. Thomas C. E. Ehrhardt A. Kay M. A. (2003 4 4 5(May 2003), 346 358, 1471-0064
(2004).Gene-based Approaches for the Repair of Articular Cartilage. Trippel S. B. Ghivizzani S. C. Nixon A. J. (2004 11 4 4(February 2004), 351 359, 1476-5462
Trumble T. N. Trotter G. W. Oxford J. R. Mc Ilwraith C. W. Cammarata S. Goodnight J. L. Billinghurst R. C. Frisbie D. D. 2001Synovial Fluid Gelatinase Concentrations and Matrix Metalloproteinase and Cytokine Expression in Naturally Occurring Joint Disease in Horses. 62 9(September 2001), 1467 1477, 0002-9645
Tuli R. Li W. J. Tuan R. S. 2003Current State of Cartilage Tissue-engineering. 5 5(August 2003), 235 238, 1478-6354
Uhlar C. M. Grehan S. Steel D. M. Steinkasserer A. Whitehead A. S. 1997Use of the Acute Phase Serum Amyloid A2 (SAA2) Gene Promoter in the Analysis of Pro- and Anti-inflammatory Mediators: Differential Kinetics of SAA2 Promoter Induction by IL-1 beta and TNF-alpha Compared to IL-6. 203 2(April 1997), 123 130, 0022-1759
van der Laan W. H. Quax P. H. Seemayer C. A. Huisman L. G. Pieterman E. J. Grimbergen J. M. Verheijen J. H. Breedveld F. C. Gay R. E. Gay S. Huizinga T. W. Pap T. 2003Cartilage Degradation and Invasion by Rheumatoid Synovial Fibroblasts is Inhibited by Gene Transfer of TIMP-1 and TIMP-3. , 10 3(February 2003), 234 242, 0969-7128
Varley A. W. Coulthard M. G. Meidell R. S. Gerard R. D. Munford R. S. 1995Inflammation-induced Recombinant Protein Expression Using Promoters from Acute-phase Protein Genes. Proceedings of the National Academy of Sciences of the United States of America, 92 12(June 1995), 5346 5350, 0027-8424
Venkatesan N. Barré L. Benani A. Netter P. Magdalou J. Fournel-Gigleux S. Ouzzine M. 2004Stimulation of Proteoglycan Synthesis by Glucuronosyltransferase-I Gene Delivery: A Strategy to Promote Cartilage Repair. 101 52(December 2004), 18087 18092, 0027-8424
Wakitani S. Goto T. Young R. G. Mansour J. M. Goldberg V. M. Caplan A. I. 1998Repair of Large Full-thickness Articular Cartilage Defects with Allograft Articular Chondrocytes Embedded in a Collagen Gel. 4 4(Winter 1998), 429 444, 2152-4955
Watson R. S. Gouze E. Levings P. P. Bush M. L. Kay J. D. Jorgensen M. S. Dacanay E. A. Reith J. W. Wright T. W. Ghivizzani S. C. 2010Gene Delivery of TGF-β1 Induces Arthrofibrosis and Chondrometaplasia of Synovium . Laboratory Investigation, 90 11(November 2010), 1615 1627, 0023-6837
Wei L. de Bri E. Lundberg A. Svensson O. 1998Mechanical Load and Primary Guinea Pig Osteoarthrosis. 69 4(August 1998), 351 357, 0001-6470
Welsch G. H. Mamisch T. C. Zak L. Blanke M. Olk A. Marlovits S. Trattnig S. 2010Evaluation of Cartilage Repair Tissue after Matrix-associated Autologous Chondrocyte Transplantation Using a Hyaluronic-based or a Collagen-based Scaffold with Morphological MOCART Scoring and Biochemical T2Mapping: Preliminary Results. 38 5(May 2010), 934 942, 0363-5465
Welter J. F. Solchaga L. A. Stewart M. C. 2004High-efficiency Non-viral Transfection of Primary Chondrocytes. , 100No.X, (July 2004), 129 146, 1543-1894
Wolf A. D. Pfleger B. 2003Burden of Major Musculoskeletal Conditions. , 81 9(November 2003), 646 656, 0042-9686
Wolfe M. M. Lichtenstein D. R. Singh G. 1999Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs. , 340 24(June 1999), 1888 1899, 0028-4793
Woods J. M. Katschke K. J. Volin M. V. Ruth J. H. Woodruff D. C. Amin M. A. Connors M. A. Kurata H. Arai K. Haines G. K. Kumar P. Koch A. E. 2001IL-4 Adenoviral Gene Therapy Reduces Inflammation, Pro-inflammatory Cytokines, Vascularization, and Bony Destruction in Rat Adjuvant-induced Arthritis. 166 2(January 2001), 1214 1222, 0022-1767
Yokoo N. Saito T. Uesugi M. Kobayashi N. Xin K. Q. Okuda K. Mizukami H. Ozawa K. Koshino T. 2005Repair of Articular Cartilage Defect by Autologous Transplantation of Basic Fibroblast Growth Factor Gene-transduced Chondrocytes with Adeno-associated Virus Vector. 52 1(January 2005), 164 170, 0004-3591
Zhang X. Mao Z. Yu C. 2004Suppression of Early Experimental Osteoarthritis by Gene Transfer of Interleukin-1 Receptor Antagonist and Interleukin-10. , 22 4(July 2004), 742 750, 0736-0266
Zhou H. S. Liu D. P. Liang C. C. 2004Challenges and Strategies: The Immune Responses in Gene Therapy. 24 6(November 2004), 748 761, 1098-1128